SCHEMBL31074264

SCHEMBL31074264

COC1(C=O)CCC(C(C)C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5567581 0.75
SCHEMBL15090427 0.72
SCHEMBL31074271 0.71
SCHEMBL4043463 0.71
SCHEMBL4041530 0.71
SCHEMBL28107803 0.71 POLB (0.30)
SCHEMBL21227330 0.70
SCHEMBL2480864 0.70
SCHEMBL26252238 0.70
SCHEMBL4041862 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676481-A1 COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA Atrogi AB (SE) 2026-01-14 EP disclosed
EP-4665321-A1 COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT Atrogi AB (SE) 2025-12-24 EP disclosed
WO-2024184408-A1 COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2024-09-12 WO disclosed
WO-2024170727-A1 COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT ATROGI AB (SE) 2024-08-22 WO disclosed